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background: Outcomes of treatment of small vessel lesion is relatively not successful with the first generation drug-eluting stents (DES). 
Biodegradable polymer second generation DES offer potential for better prognosis in comparison with permanent polymer stents. However, benefits 
of biodegradable polymer DES has not been clarified as compared with permanent polymer stents in small vessel. The aim of this study was to 
compare efficacy and safety of abluminal biolimus-eluting biodegradable polymer stents and zotarolimus-eluting permanent polymer stents in small 
vessel.
Methods: This study was sub-study of OPTIMA-C study which compares abluminal biolimus-eluting biodegradable polymer stents and zotarolimus-
eluting permanent polymer stents. A total of 232 patients ((148 men, 63.7±9.8 years) who needed small vessel stenting were prospectively 
randomized into abluminal biolimus-eluting biodegradable polymer stent (Group I, n=115) or zotarolimus-eluting permanent polymer stent (Group II, 
n=117). Clinical outcomes of one year were investigated in both groups and all patients underwent follow up coronary angiography (CAG).
results: There was no difference between abluminal biolimus-eluting biodegradable polymer stent group and zotarolimus -eluting permanent 
polymer stent group in demographic data and baseline QCA data. In follow up CAG data, late loss of group I tends to lower than that of group II, 
however there was no statistical significance (0.14 ± 0.29 mm vs. 0.28 ± 0.37mm, p=0.075). There was no in-stent restenosis and major adverse 
cardiac events (MACE) in both groups.
conclusions: Both second generation DES showed improved outcome in treating small vessel disease. The safety and efficacy of abluminal 
biolimus-eluting biodegradable polymer stents were not inferior to those of zotarolimus-eluting permanent polymer stents. Although there was no 
statistical significance between the two groups, the late loss of abluminal biolimus-eluting biodegradable polymer stent tend to lower than that of 
zotarolimus-eluting permanent polymer stent in patients with stent diameter of less than 2.75 mm .
